Pharmacogenomics is the study of how genes affect a person’s response to drugs. Advances in the understanding of common genetic variations have made it possible for doctors to begin to use information about a person’s genetic makeup to help choose drugs and drug doses that are likely to work best for that person.
This is a new science and so far only a small number of drugs, mostly for cancer treatment, have been identified to be used in this way. But the field is growing quickly and many more drugs are being tested for their pharmacogenomic properties.
Health Quality Ontario Reviews Emerging Pharmacogenomic Tests
In 2011, the Ontario Health Technology Advisory Committee gathered information about emerging pharmacogenomics testing. Of the many drugs being tested, the Committee came up with a list of those that should be given priority in Ontario for upcoming health technology assessment.
The Ministry of Health and Long-Term Care has accepted this recommendation.
The Ministry of Health and Long-Term Care has provided the following response: The Genetics Testing Advisory Committee was established in April 2014 with a three-year mandate to review the clinical utility and validity of genetic tests and provide advice to the Ministry of Health and Long-Term Care on the provision of genetic tests in Ontario. Some of the functions of the committee, including the responsibility to make recommendations about which tests receive public funding, have been transferred to Health Quality Ontario, which has established its Ontario Genetics Advisory Committee.